Kaleido Biosciences Reports Third Quarter 2021 Financial Results
Kaleido Biosciences (Nasdaq: KLDO) announced positive results from its Phase 1 study of KB295 for mild-to-moderate ulcerative colitis, achieving its primary goal of safety and tolerability. The study indicated significant reductions in biomarkers linked to disease activity. The company also plans to initiate Phase 2 trials for KB295 in ulcerative colitis and KB109 in COPD by mid-2022. For Q3 2021, Kaleido reported a net loss of $23.1 million ($0.54 per share) and increased R&D expenses of $17.4 million, partially offset by a decrease in G&A expenses to $5.1 million.
- Successful Phase 1 study of KB295 showing significant biomarker reduction.
- Plans to initiate Phase 2 trials for KB295 and KB109 in 2022.
- Decrease in G&A expenses to $5.1 million from $7.2 million.
- Q3 2021 net loss remains at $23.1 million, indicating ongoing financial challenges.
- Increase in R&D expenses to $17.4 million, raising concerns about cash management.
--Achieved primary objective of safety and tolerability in clinical study evaluating KB295 in mild-to-moderate ulcerative colitis; meaningful reduction observed in key biomarkers correlated with disease activity and inflammation--
--Remain on track to initiate Phase 2 clinical trials of KB109 in COPD and KB295 in UC in first half 2022--
LEXINGTON, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today reported financial results for the third quarter ended September 30, 2021.
“This has been a productive quarter for Kaleido, highlighted by the reporting of positive data from our first-in-human study in mild-to-moderate ulcerative colitis paving a clear path forward to advance KB295 into a Phase 2 clinical trial under an IND next year,” said Dan Menichella, President and Chief Executive Officer of Kaleido. “Additionally, we are continuing to work closely with our partners at the COPD Foundation and remain on track to initiate a Phase 2 trial of KB109 in COPD in the first half of 2022. We are excited to initiate clinical trials in these two indications next year and look forward to demonstrating the immunomodulatory effect of our unique, microbiome metabolic therapies.”
Recent Program and Corporate Highlights
- In October, Kaleido announced the primary objective of safety and tolerability in the non IND/CTA K030 study evaluating KB295 in mild-to-moderate ulcerative colitis (UC) was achieved. Findings from the study revealed KB295 was well tolerated across subjects, including those taking 5-ASA medications and/or biologics, and no product-emergent serious adverse events were reported. In addition, subjects receiving KB295 experienced a reduction in three biomarkers known to be associated with UC disease activity, fecal calprotectin (FCP), fecal lactoferrin, and FimH. These results, together with pre-clinical data from ex vivo studies, support the Company’s plans to initiate a phase 2 trial, under an Investigational New Drug (IND) application and Clinical Trial Application (CTA), of KB295 in mild-to-moderate UC in the first half of 2022.
- The Company remains on track to initiate a Phase 2 clinical trial of KB109 in patients with chronic obstructive pulmonary disease (COPD) in the first half of 2022, in collaboration with the COPD Foundation.
Third Quarter Financial Results
Kaleido reported a net loss of
Research and development (R&D) expenses were
General and administrative (G&A) expenses were
As of September 30, 2021, the Company reported cash and cash equivalents of
About Microbiome Metabolic Therapies (MMT™)
Kaleido’s Microbiome Metabolic Therapies, or MMTs, are designed to drive the function and distribution of the microbiome’s existing microbes in order to decrease or increase the production of metabolites, or to advantage or disadvantage certain bacteria in the microbiome community. The Company’s initial MMT candidates are targeted, synthetic glycans that are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. Kaleido utilizes its discovery and development platform to study MMTs in microbiome samples to rapidly advance MMT candidates into clinical studies in healthy subjects and patients. These human clinical studies may be conducted under regulations supporting research with food, evaluating safety and tolerability and impact on the microbiome. For MMT candidates that are developed as therapeutics, the Company currently conducts and will conduct clinical trials under an Investigational New Drug (IND) or regulatory equivalent outside the U.S., often in Phase 2 or later development.
About Kaleido Biosciences
Kaleido Biosciences is a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis. The Company has built a proprietary product platform to enable the rapid and cost-efficient discovery and development of novel Microbiome Metabolic Therapies (MMT™). MMTs are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the gut’s existing microbes. Kaleido is advancing a broad pipeline of MMT candidates with the potential to address a variety of diseases and conditions with significant unmet patient needs. To learn more, visit https://kaleido.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding clinical study plans and timelines, plans and timing for regulatory filings, and the Company’s business focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the breadth of our pipeline of product candidates, the strength of our proprietary product platform, the efficiency of our discovery and development approach, the clinical development and safety profile of our MMT candidates and their therapeutic potential, whether and when, if at all, regulatory agencies will approve our IND application or clinical trial applications for KB295 or KB109, whether and when, if at all, our MMT candidates will receive approval from the U.S. Food and Drug Administration or other regulatory agencies and for which, if any, indications, competition from other biotechnology companies, and other risks identified in our SEC filings, including our most recent Form 10-K, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
Kaleido Biosciences, Inc. and Subsidiaries
Condensed Consolidated Statement of Operations (Unaudited)
(in thousands, except share and per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration revenue | $ | 104 | $ | 482 | $ | 612 | $ | 732 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 17,411 | 15,659 | 52,229 | 41,629 | ||||||||||||
| General and administrative | 5,106 | 7,201 | 16,351 | 18,677 | ||||||||||||
| Total operating expenses | 22,517 | 22,860 | 68,580 | 60,306 | ||||||||||||
| Loss from Operations | (22,413 | ) | (22,378 | ) | (67,968 | ) | (59,574 | ) | ||||||||
| Other (expense) income, net | (672 | ) | (753 | ) | (2,048 | ) | (2,030 | ) | ||||||||
| Net loss | $ | (23,085 | ) | $ | (23,131 | ) | $ | (70,016 | ) | $ | (61,604 | ) | ||||
| Net loss per share—basic and diluted | $ | (0.54 | ) | $ | (0.65 | ) | $ | (1.68 | ) | $ | (1.89 | ) | ||||
| Weighted-average common shares outstanding—basic and diluted | 42,577,570 | 35,554,128 | 41,613,473 | 32,605,592 | ||||||||||||
Kaleido Biosciences, Inc. and Subsidiaries
Condensed Consolidated Balance Sheet Data (Unaudited)
(in thousands)
| September 30, 2021 | December 31, 2020 | |||||||
| Assets: | ||||||||
| Cash and cash equivalents | $ | 55,657 | $ | 46,222 | ||||
| Other assets | 12,147 | 13,122 | ||||||
| Total assets | $ | 67,804 | $ | 59,344 | ||||
| Liabilities and stockholders' equity | ||||||||
| Liabilities | $ | 38,604 | $ | 38,848 | ||||
| Stockholders' equity | 29,200 | 20,496 | ||||||
| Total liabilities and stockholders' equity | $ | 67,804 | $ | 59,344 | ||||
Contacts:
Kaleido Biosciences
William Duke, Jr.
Chief Financial Officer
617-890-5772
william.duke@kaleido.com
Investors and Media
Kotaro Yoshida
Argot Partners
212-600-1902
kaleido@argotpartners.com
FAQ
What were Kaleido's Q3 2021 financial results?
What are the upcoming clinical trials for KLDO?
How did Kaleido perform in its recent clinical study?
What is the outlook for Kaleido Biosciences in 2022?
